I am pretty sure I have read every article, PR out there on RLFTF. My question is; Since they have been operating with the Expanded Use designation since July do we know how many patients have used the drug to date? Secondly, isn't this basically a free look at the results of the treatment? I would imagine the trial will follow pretty close to what the results have been in the expanded use arm. TIA
(1)
(0)
Mondobiotech Holding AG Basel (RLFTF) Stock Research Links